Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Phase 2 Active not recruiting 15 enrolled M.D. Anderson Cancer Center

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial investigates how well elotuzumab works in treating patients with JAK2-mutated myelofibrosis. Elotuzumab may help to control myelofibrosis and/or help to improve blood cell count and bone marrow function.

Timeline

Start: 2021-02-10
Primary completion: 2027-12-31
Completion: 2027-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Elotuzumab	Monoclonal antibody	—	Intravenous

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Summary

Timeline

Drugs

Indications